Organization
Second Positive Phase 2 Trial Boosts Confidence in Alnylam’s RNAi Blood Pressure Med, Supporting Roche’s $2.8 Billion Biobucks Bet
Alnylam RNAi blood pressure medication, Zilebesiran, Phase 2 trial success, Systolic blood pressure reduction, Roche partnership, $2.8 billion milestone payments, Hypertension therapy, KARDIA-2 study
Headlight: PillPack Co-Founder Backs Mental Health Startup’s $18M Funding in Transformative Care Mission
PillPack, Amazona, Clinician, Practice Experience
Scion Life Sciences Emerges with $310M Fund to Nurture Innovative Biotechnology Startups
Scion, Scion Life Sciences, Investments, Mature
Takeda Reports Lower Profits in Latest Quarter, Closes $300M Deal with Protagonist
Protagonist, profit, Takeda, Quarter, Report (document), earnings, Takeda’s